---
title: "Cell Source delays annual report for year ended December 31, 2024"
url: "https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-28"
section: "Distress"
tickers: "OTC:CLCS"
source: "https://www.sec.gov/Archives/edgar/data/1569340/000164117225001080/formnt10-k.htm"
summary: "The company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date."
---

By the aibio.space news desk.

Sources

- [Cell Source, Inc. NT 10-K (2025-03-28)](https://www.sec.gov/Archives/edgar/data/1569340/000164117225001080/formnt10-k.htm)

[CLCS](https://aibio.space/companies/cell-source/)

2025-03-28

# Cell Source delays annual report for year ended December 31, 2024

Tickers [CLCS](https://aibio.space/companies/cell-source/)

The company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date.

## Key facts

- **Company**: Cell Source, Inc. (OTC: CLCS)

- **News type**: Distress

- **Primary source**: [Cell Source, Inc. NT 10-K (2025-03-28)](https://www.sec.gov/Archives/edgar/data/1569340/000164117225001080/formnt10-k.htm)

*The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Cell Source, Inc. said it is unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 on time without unreasonable effort or expense.

The company filed a Form 12b-25, a notice that gives a company a short grace period for a late report. For an annual report, that period runs to the fifteenth calendar day after the due date.

Cell Source blamed "a delay experienced by the Registrant in completing its financial statements and other disclosures" in the report. It said it is still compiling the information required to complete the filing. The notice refers to the deadline as the March 31, 2024 filing date that applies to smaller reporting companies.

The company said it expects to file the annual report no later than the fifteenth calendar day after the prescribed filing date. It said it has filed all other periodic reports required in the preceding 12 months and does not expect a significant change in results of operations from the last fiscal year, according to the [notice](https://www.sec.gov/Archives/edgar/data/1569340/000164117225001080/formnt10-k.htm).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CLCS

Cell Source, Inc.

OTC · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cell Source delays annual report for year ended December 31, 2024", 2025-03-28, https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/